DDInter596 DDInter979
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma. Along with [daratumumab], another anti-CD38 mAb, isatuximab constitutes a novel treatment modality for patients with difficult-to-treat multiple myeloma. Following three consecutive years on the yearly "Antibodies to watch" list published in "mAb", a peer-reviewed scientific journal dedicated to antibody research,[A38676,A191826,A191829] isatuximab was granted Orphan Drug designation and approved on March 2nd, 2020, for the treatment of multiple myeloma.[L12099,L12102] It is manufactured by Sanofi-Aventis U.S. under the brand name Sarclisa.
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Olaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Doxorubicin {u} (Compound) treats {v} (Disease) stomach cancer
stomach cancer {u} (Disease) is treated by {v} (Compound) Mitomycin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mitomycin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Mitomycin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Doxorubicin {u} (Compound) upregulates {v} (Gene) STAP2
STAP2 {u} (Gene) is upregulated by {v} (Compound) Mitomycin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Doxorubicin {u} (Compound) downregulates {v} (Gene) BLCAP
BLCAP {u} (Gene) is upregulated by {v} (Compound) Mitomycin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Doxorubicin {u} (Compound) downregulates {v} (Gene) BLCAP
BLCAP {u} (Gene) is downregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isatuximab
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Doxorubicin (Compound) treats stomach cancer (Disease) and stomach cancer (Disease) is treated by Mitomycin (Compound) and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mitomycin (Compound) and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Doxorubicin (Compound) upregulates STAP2 (Gene) and STAP2 (Gene) is upregulated by Mitomycin (Compound) and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Doxorubicin (Compound) downregulates BLCAP (Gene) and BLCAP (Gene) is upregulated by Mitomycin (Compound) and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Doxorubicin (Compound) downregulates BLCAP (Gene) and BLCAP (Gene) is downregulated by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin (Compound) resembles Daunorubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a minor interaction that can limit clinical effects when taken with Melphalan and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab